Press Releases
Michael Mullette Joins MAPS PBC Senior Leadership as Chief Operating Officer
Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA Hire represents a major step forward in...
MAPS PBC Adopts Charter for Independent Ethics Review Board
FOR IMMEDIATE RELEASE Independent members will inform continual iteration and improvement of ethical governance of MDMA-assisted therapy research and therapist training program Independent Ethical Review Board engages outside experts to provide additional layer of...
MAPS Receives Grant of Appeal and Authorization to Study MDMA in Healthy Volunteer Therapists
Phase 1 clinical trials of MDMA-assisted therapy for healthcare providers will measure development of self-compassion, professional quality of life, and professional burnout among clinicians delivering the treatment to patients The study, one of few legal means by...
MAPS’ Phase 3 Trial of MDMA-Assisted Therapy for PTSD Achieves Highly Statistically Significant Results for Patients with Severe, Chronic PTSD
The highly statistically significant results and excellent safety record suggest MDMA-assisted therapy will be an effective treatment for severe, chronic PTSD 67% of participants who received three MDMA-assisted therapy sessions no longer qualified for a PTSD...
First Controlled Trial of Cannabis for the Treatment of PTSD Raises no Safety Concerns, Further Research is Needed to Determine Efficacy
Widespread anecdotal reports of benefit have led to self-treatment of the symptoms of posttraumatic stress disorder (PTSD) with cannabis among Veterans and others; the safety and potential efficacy of such treatments have not previously been studied through randomized...
MAPS Public Benefit Corporation Expands Talent with Three Leadership Hires
MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association of Psychedelic Studies (MAPS), has recently expanded their team with three new leaders bringing decades of...
MAPS-Sponsored Pilot Study: MDMA-Assisted Psychotherapy for PTSD in Couples May Reduce PTSD Symptoms, Improve Couples’ Happiness
Cognitive-behavioral conjoint therapy (CBCT) for posttraumatic stress disorder (PTSD), when combined with MDMA, resulted in significant improvements in PTSD symptoms Six couples, in which one partner was diagnosed with PTSD, participated in a seven-week protocol; both...
Numinus and MAPS Public Benefit Corporation Announce Collaboration Agreement to Seek Approval of MDMA-Assisted Psychotherapy for PTSD Single-Arm, Open-Label Trial
Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support...
Study: MDMA-Assisted Psychotherapy May Reduce Anxiety for Those Diagnosed with Life-Threatening Illness
Pilot study explored the application of MDMA-assisted psychotherapy in 18 individuals experiencing moderate to severe anxiety following diagnosis with a life-threatening illness The primary outcome, change in State-Trait Anxiety Inventory (STAI) Trait Scores,...
Study: MDMA-Assisted Psychotherapy Will Be Cost-Effective in the Treatment of PTSD
Healthcare cost savings of MDMA-assisted psychotherapy for PTSD estimated to be greater than $103.2 million with a return of 5,553 Quality of Life Years per 1,000 patients Santa Cruz, CA, October 14, 2020 – A peer-reviewed study published today in the research journal...